Index RUT
P/E -
EPS (ttm) -2.20
Insider Own 2.31%
Shs Outstand 48.97M
Perf Week -2.63%
Market Cap 781.23M
Forward P/E -
EPS next Y -0.97
Insider Trans -6.27%
Shs Float 47.85M
Perf Month -14.06%
Income -107.59M
PEG -
EPS next Q -0.35
Inst Own 103.50%
Short Float 9.26%
Perf Quarter 5.21%
Sales 233.25M
P/S 3.35
EPS this Y 41.26%
Inst Trans -0.41%
Short Ratio 9.97
Perf Half Y 67.54%
Book/sh 9.45
P/B 1.69
EPS next Y 25.03%
ROA -9.94%
Short Interest 4.43M
Perf Year -23.94%
Cash/sh 9.33
P/C 1.71
EPS next 5Y -
ROE -19.06%
52W Range 9.00 - 24.17
Perf YTD 2.97%
Dividend Est. -
P/FCF -
EPS past 5Y -45.48%
ROI -11.96%
52W High -34.01%
Beta 1.73
Dividend TTM -
Quick Ratio 11.16
Sales past 5Y 78.51%
Gross Margin 35.60%
52W Low 77.22%
ATR (14) 0.91
Dividend Ex-Date -
Current Ratio 11.73
EPS Y/Y TTM -137.82%
Oper. Margin -25.14%
RSI (14) 42.62
Volatility 6.03% 4.71%
Employees 1170
Debt/Eq 0.85
Sales Y/Y TTM -1.70%
Profit Margin -46.12%
Recom 2.20
Target Price 18.00
Option/Short Yes / Yes
LT Debt/Eq 0.84
EPS Q/Q -457.68%
Payout -
Rel Volume 1.19
Prev Close 17.16
Sales Surprise -1.94%
EPS Surprise -362.41%
Sales Q/Q -5.13%
Earnings May 07 AMC
Avg Volume 444.54K
Price 15.95
SMA20 -6.32%
SMA50 -5.65%
SMA200 8.29%
Trades
Volume 530,468
Change -7.05%
Date
Action
Analyst
Rating Change
Price Target Change
May-03-24 Downgrade
B. Riley Securities
Buy → Neutral
$22 → $19
Apr-04-24 Resumed
Jefferies
Buy
$17 → $21
Mar-13-24 Reiterated
Needham
Buy
$19 → $18
Aug-17-23 Initiated
Morgan Stanley
Equal-Weight
$16
Aug-10-23 Downgrade
Stephens
Overweight → Equal-Weight
$15
Jul-18-23 Downgrade
UBS
Buy → Neutral
$28 → $17
Jul-17-23 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Jul-13-23 Downgrade
SVB Securities
Outperform → Market Perform
$30 → $10
Jan-19-22 Upgrade
ROTH Capital
Neutral → Buy
$90
Nov-05-21 Downgrade
ROTH Capital
Buy → Neutral
$78 → $90
Oct-19-21 Resumed
B. Riley Securities
Buy
$81
Jul-16-21 Initiated
BTIG Research
Buy
$80
Mar-15-21 Initiated
UBS
Buy
$84
Mar-02-21 Resumed
Needham
Buy
$73
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$54
Jan-08-20 Initiated
Stephens
Overweight
$21
Jul-01-19 Resumed
Needham
Buy
$22
Oct-10-18 Initiated
B. Riley FBR
Buy
$22
Aug-13-18 Reiterated
Cowen
Outperform
$11 → $16
Jul-02-18 Reiterated
Needham
Buy
$11 → $19
Show Previous Ratings
May-03-24 10:12AM
06:41AM
Apr-30-24 08:30AM
Apr-25-24 10:02AM
Mar-13-24 09:16AM
05:52PM
Loading…
Mar-12-24 05:52PM
05:30PM
04:05PM
Feb-27-24 08:30AM
Feb-15-24 10:00AM
Feb-13-24 09:55AM
Nov-27-23 08:30AM
Nov-21-23 03:26PM
Nov-16-23 08:30AM
Nov-09-23 05:23PM
06:05PM
Loading…
Nov-08-23 06:05PM
04:05PM
Nov-02-23 08:30AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
Oct-12-23 08:30AM
Oct-10-23 08:30AM
Oct-09-23 04:05PM
Sep-14-23 08:30AM
Aug-10-23 07:14AM
Aug-09-23 05:30PM
04:05PM
Aug-02-23 08:30AM
Jul-31-23 08:53AM
Jul-23-23 08:17AM
12:24PM
Loading…
Jul-13-23 12:24PM
11:17AM
Jul-12-23 04:05PM
12:56PM
Jun-29-23 08:39AM
May-25-23 08:02AM
May-12-23 07:15AM
May-04-23 06:05PM
04:05PM
Apr-27-23 10:02AM
08:30AM
Apr-25-23 08:30AM
Apr-01-23 08:54AM
Mar-28-23 08:30AM
Mar-16-23 03:46AM
Mar-13-23 06:00AM
Mar-08-23 01:15PM
Feb-23-23 06:40PM
04:05PM
Feb-15-23 08:30AM
Jan-29-23 07:31AM
Jan-26-23 10:55AM
Jan-18-23 08:30AM
Dec-20-22 08:30AM
Dec-19-22 07:15AM
Nov-08-22 06:56AM
Nov-07-22 08:10PM
05:03AM
Nov-03-22 06:45PM
04:05PM
Oct-27-22 08:30AM
05:32AM
Sep-08-22 08:30AM
Aug-08-22 02:42PM
(Investor's Business Daily) +6.83%
Aug-06-22 10:18AM
Aug-05-22 09:55AM
Aug-04-22 07:15PM
04:05PM
Jul-28-22 08:30AM
Jul-01-22 08:57AM
May-05-22 07:05PM
04:05PM
Apr-28-22 08:30AM
Apr-20-22 05:59PM
(American City Business Journals)
Apr-19-22 12:24PM
(American City Business Journals)
Apr-18-22 03:11PM
(American City Business Journals)
08:30AM
Mar-30-22 05:00PM
Mar-11-22 03:40PM
Feb-24-22 06:30PM
04:05PM
Feb-23-22 10:00AM
Feb-17-22 03:02PM
Feb-15-22 08:30AM
Feb-09-22 09:29AM
Feb-08-22 09:38AM
Feb-01-22 05:38PM
Jan-31-22 05:35PM
Jan-28-22 05:46AM
Jan-27-22 08:30AM
Jan-26-22 05:38PM
Jan-21-22 05:38PM
09:38AM
Jan-05-22 01:38PM
08:30AM
Dec-16-21 03:38AM
Dec-15-21 01:15PM
Dec-13-21 04:38PM
Dec-05-21 08:05AM
Nov-26-21 04:01PM
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SHELTON JERRELL Chief Executive Officer Mar 25 '24 Sale 17.54 2,631 46,154 692,182 Mar 26 08:09 PM Sawicki Mark W Chief Scientific Officer Mar 25 '24 Sale 17.54 1,367 23,980 77,444 Mar 26 08:08 PM STEFANOVICH ROBERT Chief Financial Officer Mar 25 '24 Sale 17.54 1,079 18,928 128,333 Mar 26 08:12 PM SHELTON JERRELL President, CEO Mar 15 '24 Option Exercise 4.80 100,000 480,000 749,253 Mar 19 07:48 PM Mandalam Ramkumar Director Mar 15 '24 Option Exercise 5.40 8,334 45,004 46,404 Mar 19 07:49 PM BADDOUR LINDA Director Mar 15 '24 Option Exercise 0.00 1,111 0 21,690 Mar 19 07:48 PM SHELTON JERRELL President, CEO Mar 15 '24 Sale 15.30 57,039 872,884 634,352 Mar 19 07:48 PM Mandalam Ramkumar Director Mar 15 '24 Sale 14.68 3,217 47,226 43,187 Mar 19 07:49 PM Sawicki Mark W Chief Scientific Officer Mar 15 '24 Sale 15.43 1,312 20,247 73,061 Mar 19 07:50 PM STEFANOVICH ROBERT Chief Financial Officer Mar 15 '24 Sale 15.43 1,035 15,972 123,662 Mar 19 07:51 PM SHELTON JERRELL President, CEO Mar 11 '24 Sale 16.35 3,723 60,880 636,951 Mar 19 07:48 PM Sawicki Mark W Chief Scientific Officer Mar 11 '24 Sale 16.35 1,418 23,188 74,373 Mar 19 07:50 PM STEFANOVICH ROBERT Chief Financial Officer Mar 11 '24 Sale 16.35 1,119 18,298 124,697 Mar 19 07:51 PM STEFANOVICH ROBERT Chief Financial Officer Mar 09 '24 Option Exercise 0.00 2,666 0 125,816 Mar 19 07:51 PM SHELTON JERRELL President, CEO Mar 09 '24 Option Exercise 0.00 8,250 0 640,674 Mar 19 07:48 PM Sawicki Mark W Chief Scientific Officer Mar 09 '24 Option Exercise 0.00 2,666 0 75,791 Mar 19 07:50 PM Hariri Robert J Director Dec 14 '23 Sale 16.89 800 13,512 12,716 Dec 18 07:19 PM Hariri Robert J Director Dec 11 '23 Sale 15.50 1,000 15,500 13,516 Dec 13 06:02 PM Sawicki Mark W Chief Scientific Officer Sep 12 '23 Option Exercise 12.79 1,000 12,790 73,125 Sep 13 05:01 PM Hariri Robert J Director Sep 06 '23 Sale 13.60 1,500 20,400 14,516 Sep 12 06:01 PM SHELTON JERRELL See Remarks Sep 01 '23 Option Exercise 1.87 54,000 100,980 659,299 Sep 05 05:53 PM SHELTON JERRELL See Remarks Sep 01 '23 Sale 14.27 26,875 383,407 632,424 Sep 05 05:53 PM STEFANOVICH ROBERT Chief Financial Officer Aug 29 '23 Option Exercise 3.07 16,000 49,120 123,150 Aug 30 05:30 PM BERMAN RICHARD J Director May 11 '23 Sale 21.51 7,203 154,906 100,000 May 12 06:22 PM SHELTON JERRELL President, CEO May 10 '23 Option Exercise 3.24 286,377 927,861 746,458 May 12 06:22 PM STEFANOVICH ROBERT Chief Financial Officer May 10 '23 Option Exercise 3.24 19,918 64,534 127,068 May 12 06:21 PM SHELTON JERRELL President, CEO May 10 '23 Sale 21.63 141,159 3,053,509 605,299 May 12 06:22 PM STEFANOVICH ROBERT Chief Financial Officer May 10 '23 Sale 21.94 19,918 437,023 107,150 May 12 06:21 PM
Index -
P/E -
EPS (ttm) -5.50
Insider Own 51.56%
Shs Outstand 21.78M
Perf Week 8.94%
Market Cap 71.66M
Forward P/E -
EPS next Y -
Insider Trans 190.66%
Shs Float 10.55M
Perf Month -35.74%
Income -181.41M
PEG -
EPS next Q -
Inst Own 14.37%
Short Float 3.73%
Perf Quarter -39.07%
Sales 14.79M
P/S 4.84
EPS this Y -
Inst Trans 377.53%
Short Ratio 5.13
Perf Half Y 52.95%
Book/sh 1.56
P/B 2.11
EPS next Y -
ROA -61.05%
Short Interest 0.39M
Perf Year -37.70%
Cash/sh 0.01
P/C 265.39
EPS next 5Y -
ROE -186.56%
52W Range 1.59 - 8.90
Perf YTD 32.98%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -322.10%
52W High -63.03%
Beta 0.43
Dividend TTM -
Quick Ratio 0.14
Sales past 5Y -
Gross Margin -42.83%
52W Low 106.92%
ATR (14) 0.41
Dividend Ex-Date -
Current Ratio 0.19
EPS Y/Y TTM -628.37%
Oper. Margin -658.47%
RSI (14) 39.53
Volatility 9.41% 11.17%
Employees -
Debt/Eq 2.02
Sales Y/Y TTM -20.93%
Profit Margin -1226.72%
Recom 1.00
Target Price 25.00
Option/Short Yes / Yes
LT Debt/Eq 0.86
EPS Q/Q -15726.96%
Payout -
Rel Volume 0.27
Prev Close 3.12
Sales Surprise -
EPS Surprise -
Sales Q/Q -8.44%
Earnings -
Avg Volume 76.70K
Price 3.29
SMA20 -12.54%
SMA50 -27.24%
SMA200 0.57%
Trades
Volume 20,982
Change 5.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-23 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$5 → $1
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Jun-22-22 Initiated
H.C. Wainwright
Buy
$15
Apr-06-22 Downgrade
Truist
Buy → Hold
$10
Jan-28-22 Initiated
Oppenheimer
Outperform
$9
Nov-24-21 Initiated
Morgan Stanley
Equal-Weight
$9
Apr-22-24 08:00AM
Apr-19-24 05:30PM
Apr-18-24 04:30PM
Apr-15-24 08:00AM
Apr-08-24 09:00AM
09:00AM
Loading…
Mar-26-24 09:00AM
Mar-20-24 09:15AM
Mar-14-24 09:15AM
Mar-12-24 09:20AM
Mar-07-24 09:35AM
Feb-23-24 04:10PM
Feb-14-24 04:05PM
Feb-01-24 09:00AM
Jan-25-24 09:00AM
Jan-18-24 01:40PM
01:00PM
Loading…
Jan-04-24 01:00PM
Jan-03-24 07:30PM
12:00PM
Nov-24-23 01:15PM
Oct-18-23 09:00AM
Sep-07-23 04:10PM
Aug-29-23 09:00AM
Jul-27-23 09:07AM
09:00AM
Jul-18-23 09:00AM
Jun-29-23 04:05PM
Jun-01-23 09:15AM
May-23-23 10:56AM
May-19-23 04:21PM
May-10-23 09:00AM
04:01PM
Loading…
May-01-23 04:01PM
Apr-27-23 09:00AM
Apr-12-23 09:00AM
Apr-05-23 09:00AM
Apr-04-23 09:00AM
Apr-03-23 09:00AM
Mar-28-23 10:55AM
09:00AM
Feb-02-23 07:53AM
Feb-01-23 04:05PM
Jan-26-23 04:17PM
Jan-11-23 01:35PM
01:22PM
Jan-06-23 08:10AM
Jan-04-23 04:10PM
Dec-05-22 08:00AM
Nov-30-22 09:55AM
Nov-10-22 05:00PM
04:10PM
09:10AM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-27-22 08:00AM
Sep-26-22 08:00AM
Sep-15-22 02:29PM
Sep-06-22 04:10PM
Aug-09-22 04:10PM
Jul-27-22 08:00AM
Jul-04-22 10:08AM
Jun-08-22 04:10PM
Jun-03-22 08:00AM
May-18-22 08:30AM
May-16-22 04:10PM
Mar-31-22 04:05PM
Mar-15-22 04:05PM
12:59PM
Feb-15-22 04:05PM
Jan-27-22 05:38PM
05:38PM
Jan-18-22 08:00AM
Dec-27-21 08:00AM
Dec-15-21 09:04AM
Dec-13-21 08:00AM
Nov-29-21 08:00AM
Nov-16-21 05:35AM
Nov-15-21 08:00AM
Nov-12-21 04:05PM
Sep-20-21 08:00AM
08:00AM
Aug-16-21 05:15PM
Aug-04-21 07:00PM
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lim Kok Thay 10% Owner Jan 12 '24 Buy 0.25 21,410,983 5,331,335 51,473,762 Jan 17 05:22 PM Hariri Robert J Chief Executive Officer Oct 05 '23 Buy 0.16 9,357,585 1,484,113 28,570,434 Oct 10 09:48 PM Hariri Robert J Chief Executive Officer Sep 29 '23 Buy 0.17 9,064,539 1,500,181 19,212,849 Oct 10 09:48 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite